StockIQpro
NASDAQ:HRMY

Harmony Biosciences Holdings, Inc.

Track all markets on TradingView
Track all markets on TradingView

Harmony Biosciences Holdings, Inc.'s revenue grew 21.5% in fiscal 2025 to $868.5M while operating margin fell to 24.0%. Free cash flow was $347.9M, 40.1% of revenue, and the diluted share count rose 1.2%.Summary generated from Harmony Biosciences Holdings, Inc.'s SEC filings. Latest annual report filed Feb 24, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$868.5M
Revenue growth+21.5%
Revenue, 5-yr CAGR+40.3%
Gross margin77.2%
Operating margin24.0%
Net margin18.3%
ROIC46.1%
Return on equity20.8%
Debt / equity0.19
Free cash flow$347.9M
FCF margin40.1%
Share count change+1.2%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue305438582715868
Operating income88120192191208
Net income35181129145159
Free cash flow98144219219348

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations